...Ana María Cubo; Marta Huélamo; María Carmen Martín-Seisdedos; Estrella Hernández-Hernández; Maria Victoria Lapresa-Alcalde; María de la O Rodríguez-Martín; María José Doyague; José María Sayagués Objectives: Universal screening for trisomy using cell-free DNA (cfDNA) has proven to be more effective...

... choice of cell-free DNA (cfDNA) testing instead of invasive diagnostic testing. Methods: We conducted a prospective descriptive study including pregnant women from the Western Barcelona public health area at high risk for fetal aneuploidy, defined as a trisomy 21 or 18 risk between 1/10 and 1/250...

... to the results of the FCT, 19–21 weeks’ anomaly scan, and maternal blood cfDNA test. FCT, first-trimester combined test; cfDNA, cell-free DNA; NT, nuchal translucency; T21, trisomy 21; T18, trisomy 18; T13, trisomy 13. Fig. 1. Protocol for pregnancy management according to the results of the FCT, 19–21 weeks...

... implementation of cell-free DNA (cfDNA) testing. Methods: We retrospectively analyzed all twin pregnancies undergoing first-trimester combined screening over a 10 years’ period. The population was stratified according to various risk cut-offs, and we examined different screening strategies for implementation...

...Emilia Kostenko; Frederic Chantraine; Katleen Vandeweyer; Maximilian Schmid; Alex Lefevre; Deanna Hertz; Laura Zelle; Jose Luis Bartha; Gian Carlo Di Renzo Objective: To evaluate the clinical and economic impact of adopting noninvasive prenatal testing (NIPT) using circulating cell-free DNA...

...Elisa Bevilacqua; Jacques C. Jani; Alexandra Letourneau; Silvia F. Duiella; Pascale Kleinfinger; Laurence Lohmann; Serena Resta; Teresa Cos Sanchez; Jean-François Fils; Marilyn Mirra; Alexandra Benachi; Jean-Marc Costa Objectives: To evaluate the failure rate and performance of cell-free DNA (cfDNA...

...Maximilian Schmid; Eric Wang; Patrick E. Bogard; Elisa Bevilacqua; Coleen Hacker; Susie Wang; Jigna Doshi; Karen White; Jennifer Kaplan; Andrew Sparks; Jacques C. Jani; Renee Stokowski Objective: To determine the performance of a targeted microarray-based cell-free DNA (cfDNA) test (Harmony...

...Elisa Bevilacqua; Elena Ordóñez; Ivan Hurtado; Laura Rueda; Eléonora Mazzone; Vincenzo Cirigliano; Jacques C. Jani Objective: To study patient choice regarding testing for sex chromosome aneuploidy (SCA) and the performance of cell-free DNA (cfDNA) screening for SCA. Methods: Patient choice...

...Francesco Crea; Matthew Forman; Rachel Hulme; Robert W. Old; Dan Ryan; Rosalyn Mazey; Michael D. Risley Objective: To develop a screening test for fetal trisomy 13, 18, and 21 using cell-free DNA from maternal blood with an automated workflow using the Ion Proton sequencing platform. Methods...

... or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Cell-free DNA Intrauterine growth restriction Preeclampsia Pregnancy Prenatal screening...

...Chanchal Sur Chowdhury; Sinuhe Hahn; Paul Hasler; Irene Hoesli; Olav Lapaire; Stavros Giaglis Introduction: The analysis of cell-free DNA from maternal blood samples has facilitated the noninvasive detection of fetal aneuploidies or hereditary Mendelian disorders. In this context, previous studies...

...Mats Hidestrand; Renee Stokowski; Ken Song; Arnold Oliphant; Julie Deavers; Mary Goetsch; Pippa Simpson; Randall Kuhlman; Mary Ames; Michael Mitchell; Aoy Tomita-Mitchell Objective: To determine the effect of shipping blood in Streck blood collection tubes (BCT) prior to processing on cell-free DNA...

...-free DNA Fetal DNA Intrauterine growth restriction Placental insufficiency Original Paper Fetal Diagn Ther 2009;26:24 28 DOI: 10.1159/000236355 Received: October 30, 2008 Accepted after revision: May 2, 2009 Published online: October 10, 2009 Total and Fetal Cell-Free DNA Analysis in Maternal...